Key result
Clopidogrel dosing algorithms based on CYP2C19 genotypes and drug interactions (tailoring 75 mg to 6-215 mg) may be supplemented by oral suspensions and alternative agents.
A letter discussing the use of oral suspension and alternative prescribing in the context of a clopidogrel pharmacogenetic algorithm.
We read with great interest the study by Saab et al, 1 which shows that all patients who received combination therapy of clopidogrel and cytochrome P540 2C19 (CYP2C19) substrates require clopidogrel dose adjustment if they are not CYP2C19*1/*1 carriers and that therapeutic dose of 75 mg clopidogrel should be tailored in patients with different genotypes (eg, lowered to 6 mg or increased to 215 mg) for the sake of efficacy and safety.We especially appreciate the new clinical pharmacogenetic algorithm they developed to optimize clopidogrel-based treatment.However, we found two points worthy of discussion and would like to share our perspectives in the following paragraphs.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2016) reported a letter. Clopidogrel pharmacogenetic dosing algorithm with oral suspension and prescribing alternatives was evaluated. Clopidogrel dosing algorithms based on CYP2C19 genotypes and drug interactions (tailoring 75 mg to 6-215 mg) may be supplemented by oral suspensions and alternative agents.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: